Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Etanercept in Active RA Despite Methotrexate Therapy in Japan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients had to be at least 18 years of age~* fulfilled the 1987 revised classification criteria for RA by in American College of Rheumatology (ACR)~* met the guidelines for the proper use of ETN in Japan (having at least 6 tender joints and 6 swollen joints~* either serum C-reactive protein more than 2 mg/dl or ESR no less than 28 mm at 1 hour, with adequate safety profiles)~* be ACR functional class I-III~* have been receiving MTX 6 mg/week for a minimum of 3 months at a stable dose for at least 4 weeks at the time of study enrollment~Exclusion Criteria:~* Patients who required concurrent use of prednisone (PSL) \>10 mg/day, or its equivalent, were excluded from study entry~* the start of dose increment of PSL equivalents within 3 months of the study enrollment~* experience of antirheumatic therapy except for MTX and PSL equivalents~* previous treatment with ETN or any other biological treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ETN Alone (Type: ACTIVE_COMPARATOR): etanercept (25mg, twice/week, s.c.)
- ETN+MTX (Type: ACTIVE_COMPARATOR): etanercept (25mg, twice/week, s.c.) combined with methotrexate (6-8mg/week)

Based on this trial design, predict the completion outcome and termination type (if applicable).